SinoMab BioScience Limited Overview
SinoMab is the first Hong Kong-based biotechnology company listed under HKEX Chapter 18A. It is a clinical-stage, pre-revenue developer of first-in-class and potential best-in-class therapeutic antibodies for autoimmune, inflammatory and other debilitating diseases. After 25 years built around the anti-CD22 antibody Suciraslimab (SM03), the company withdrew Suciraslimab's rheumatoid arthritis BLA in July 2025. It has since re-centred on SM17, a global first-in-class anti-IL-25 receptor (IL-17RB) antibody now in a ~210-patient Phase 2 atopic dermatitis trial in China, with IBD as a second indication. Earlier assets are an anti-γc (CD132) antibody, hC2, for alopecia areata and vitiligo, and a RANKL × sclerostin bispecific for osteoporosis. In 2026 the company pivoted to an "asset-light, high-efficiency" model: it exited the Haikou plant lease and agreed to sell the Suzhou campus for RMB280 m. Value realisation now depends on out-licensing. The company also holds residual economics in the BTK inhibitor SN1011, which was sublicensed by Everest Medicines to Travere Therapeutics in June 2026.
Company's own description (Interim Results 2026, Annual Report 2025). The company describes itself as a Hong Kong-based biopharmaceutical company dedicated to discovering, researching and developing innovative therapeutic antibody drugs. Its focus is autoimmune, inflammatory and other debilitating diseases with significant unmet need, using novel targets and novel mechanisms of action. Its stated R&D philosophy is "differentiated innovation" toward First-in-Class (FIC) and Best-in-Class (BIC) antibodies. Its stated operating model since 1H 2026 is "asset-light, high-efficiency": internal resources go to discovery, translational science and clinical development, while CMC and GMP manufacturing are outsourced to CDMOs and studies to CROs. The Annual Report 2025 still described "integration of our Hong Kong-based innovative R&D team and PRC-based manufacturing capabilities". The interim language marks the formal abandonment of in-house commercial-scale manufacturing. The stated vision is "to become a global leader in the development of innovative therapeutics for immunological and other debilitating diseases".
Business model. SinoMab has no product revenue. Its income statement opens with "other income and gains" (bank interest, fair-value gains on wealth-management products, government grants, FX gains), which totalled RMB29.3 m in FY2025 and RMB23.5 m in 1H 2026. Expenses are R&D costs and administrative costs. The intended monetisation is out-licensing and partnering (regional or global licences, co-development) of clinical-stage assets. Management called this "the Company's core strategy" in the 2025 Chairman's Statement. Earlier plans for self-commercialisation are now subordinate. Those plans included a marketing team built for Suciraslimab in RA and a commercial-scale Suzhou plant. The only existing licensing economics are with Everest Medicines on SN1011: single-digit percentages of downstream upfronts, double-digit percentages of non-renal milestones and single-digit percentages of renal milestones, per the 7 April 2026 licence.
Revenue-model mix (FY2025). Product 0%; service 0%; subscription 0%; licensing 0% recognised as revenue. Licensing is the prospective model.
Value-chain position. The company has historically been vertically integrated: target discovery → antibody engineering (proprietary "framework-patching" humanisation) → preclinical → clinical → CMC/GMP → planned commercialisation. From 2026 it is repositioning to the discovery and early/mid-clinical development end of the chain, with manufacturing outsourced and late-stage development and commercialisation expected to sit with licensees.
Customer types (prospective). Global and Chinese pharmaceutical companies as licensees or partners. Ultimately, patients and prescribers in dermatology, gastroenterology, rheumatology, respiratory medicine and bone health.
End-markets. Atopic dermatitis (AD), inflammatory bowel disease (Crohn's disease and ulcerative colitis), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), idiopathic pulmonary fibrosis (IPF), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, alopecia areata (AA), vitiligo, osteoporosis, non-Hodgkin's lymphoma (SM09), and Alzheimer's disease or MCI as an exploratory CNS application of Suciraslimab.
Independent characterisation. SinoMab is best understood as a sub-scale, single-modality antibody discovery house. It is now a one-key-asset story (SM17) with a two-asset preclinical option set (hC2, RANKL×SOST bsAb) and a royalty-like residual on SN1011. The 2025 decision to drop the RA BLA after communications with CDE wrote off the company's historic flagship thesis. That thesis was eight years of public positioning of SM03 as the first anti-CD22 mAb for RA. The 2026 asset sales convert stranded manufacturing capex into runway. The equity is now effectively a binary-weighted option on (i) SM17 Phase 2 AD data, guided for 1Q 2027, and (ii) management's ability to strike an ex-China licence.
Strategy
Stated strategic themes (Interim 2026; AR 2025 Chairman's Statement), paraphrased by theme:
-
Differentiated innovation: focus on FIC/BIC antibodies against novel pathways (alarmins, γc, non-depleting CD22, multispecifics).
-
Asset-light, high-efficiency operating model: exit fixed manufacturing (Haikou lease terminated; Suzhou being sold); use CROs and CDMOs for process development, pilot-scale, GMP and clinical supply.
-
Out-licensing as core strategy: global and regional licences, co-development, technology licensing, with emphasis on SM17, hC2 and multispecific programmes. Management attended JPM Healthcare Conference (Jan 2026), LifeArc Translational Science Summit and BIO 2026.
-
Indication expansion of SM17: "pipeline-in-a-drug" across AD → IBD → asthma, IPF and CRSwNP.
-
Multispecific build-out: use validated targets as building blocks for bispecifics and multispecifics, led by the osteoporosis bsAb.
-
Capability partnerships: SYSU-IAS joint lab; exploring AI for target identification (AR 2025).
Initiatives in the last 24 months.
No quantified targets were identified.
Cost programmes: FY2025 R&D team optimisation (employment costs −RMB9.5 m) and admin staff optimisation (−RMB16.4 m). No formal savings target was published.
Medium-term financial targets or guidance: none published. The company gives only pipeline timelines (above) and a use-of-proceeds schedule running to end-2027 or 2028.
Products & Services
All products sit in the single R&D segment. None is marketed. Pricing models are not applicable or not publicly disclosed.
SM17 — anti-IL-25 receptor (IL-17RB) mAb (key product)
Description: Global first-in-class humanised IgG4-κ mAb blocking the receptor of the alarmin IL-25 on ILC2s and Th2 cells. It suppresses downstream IL-4, IL-5, IL-9 and IL-13. Preclinical data also show Th17 inhibition and anti-fibrotic activity (Interim 2026).
Origin: The company states it has been "entrusted by LifeArc" (UK medical research charity) to develop and commercialise SM17 in all fields worldwide. LifeArc's precise economic interest (royalties or milestones) is not publicly disclosed.
Clinical status: - US Phase 1 in healthy volunteers (77 subjects) completed 2023.
-
China Phase 1a bridging completed May 2024.
-
China Phase 1b in AD (32 patients) positive April 2025. High dose (600 mg per media reports): NRS-4 itch response 91.7%, EASI-75 75%, IGA 0/1 41.7%.
-
Subcutaneous bridging study (30 healthy subjects) positive topline 25 March 2026: one Grade 1 injection-site rash and no ≥Grade 3 drug-related TEAE or SAE.
-
Phase 2 AD (NCT07445919, SM17-201): randomised, double-blind, placebo-controlled, dose-finding, five arms (1:1:1:1:1), ~210 patients in China, SC formulation. First patient dosed 31 March 2026; 86 enrolled by 30 June 2026. Enrolment completion targeted 3Q 2026; topline guided 1Q 2027. ClinicalTrials.gov lists estimated primary completion as 25 April 2027.
-
Second Phase 2 in AD being prepared in Australia.
-
IBD (CD and UC) IND approved by NMPA on 24 February 2026; Phase 2a in UC under evaluation.
-
IPF IND (US and China) planned per the Annual Report 2025.
Target customers: Dermatologists (moderate-to-severe AD) and gastroenterologists (IBD); potentially pulmonologists (asthma, IPF, CRSwNP).
Key differentiation claim: Faster and deeper itch relief than IL-4/IL-13 agents, with safety superior to JAK inhibitors. This is the company's claim based on cross-trial comparison, which is a methodological caveat. "Pipeline-in-a-drug" positioning.
Suciraslimab (SM03) — anti-CD22 mAb (former flagship)
Description: Potential global first-in-class, non-depleting anti-CD22 mAb. The company's positioning: "B-cell modulation without depletion", "dual mechanism and dual regulation", and "organ protection" (preclinical proteinuria reduction in a lupus model).
Status: RA Phase 3 met its primary endpoint in April 2023: ACR20 ≈50% at week 24, rising to >65% at week 52 and >70% through week 104 of extension. BLA accepted September 2023, then voluntarily withdrawn 14 July 2025 after CDE communications. Media citing the company reported the need for supplementary early-stage efficacy data.
Now: SLE Phase 2 proof-of-concept in China "remains under evaluation as part of longer-term plans" (Interim 2026). This is a softer stance than the "advance at full speed" language of July 2025. IND enablement for Alzheimer's disease is planned.
Publications: Journal of Neuroinflammation (Feb 2025); Journal of Translational Autoimmunity (Jun 2026).
IP: 4 PRC and 4 US invention patents (US patents also cover SM06), plus 1 South Africa patent.
Anti-CGC antibody (hC2) — anti-common-gamma-chain (CD132/γc) mAb
Description: In-house first-in-class humanised anti-γc antibody that modulates signalling of IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. It partially preserves IL-2 signalling (~50%), which the company says helps maintain Treg function, and it avoids the TEC-kinase off-target effects of JAK inhibitors.
Data: Journal of Immunology (Mar 2025); SID Annual Meeting 2026 (Chicago, May 2026); Journal of Investigative Dermatology (Jun 2026). Humanised AA model hair-loss reversal p<0.001; vitiligo depigmentation reduction p<0.05.
Status: CMC optimisation and IND-enabling toxicology. IND for AA to FDA and NMPA simultaneously targeted 4Q 2026. First-in-human study end-2026 or early 2027; New Zealand and Australia considered as sites. Vitiligo is the follow-on indication.
Bispecific antibody (bsAb) — RANKL × sclerostin
Description: First-in-class bispecific designed to both promote bone formation (anti-SOST) and inhibit resorption (anti-RANKL). In-house studies show superior bone mineral density and microarchitecture versus denosumab and romosozumab (company claim).
Status: CMC optimisation and NHP toxicology; IND targeted 1H 2027. The company also cites FDA's December 2025 recognition of BMD as a clinical endpoint as an accelerator.
SM06 — second-generation humanised anti-CD22
- Humanised via proprietary framework-patching; in vitro data suggest enhanced immunomodulation and half-life versus SM03. IND-enabling and CMC optimisation. PCT filed 2025.
SM09 — framework-patched humanised anti-CD20
- Targets an epitope distinct from rituximab, obinutuzumab and ofatumumab. Indications: NHL and autoimmune diseases. IND-enabling stage I. IP: 2 PRC and 3 US patents, plus one each in the EU, India, Singapore and Japan.
SN1011 (EVER001 / civorebrutinib) — third-generation covalent reversible BTK inhibitor (out-licensed)
Status: - Four NMPA INDs (SLE 2020; pemphigus 2021; MS 2022; NMOSD 2022).
-
Renal rights licensed to Everest Medicines in 2021; remaining global rights licensed 7 April 2026.
-
Everest reported positive Phase 1b/2a primary membranous nephropathy data (ERA 2025).
-
Everest–Travere licence (2 June 2026): US$112.5 m upfront, up to US$1.03 bn milestones across up to five indications, tiered high-single- to double-digit royalties to Everest.
SinoMab economics: Single-digit % of downstream upfronts; double-digit % of non-renal milestones; single-digit % of renal milestones. The cash amount SinoMab receives from the Travere upfront is not publicly disclosed. Arithmetic bound for illustration only: a single-digit share of US$112.5 m implies ~US$1–10 m. Whether co-licensor Evopoint shares in this is not disclosed.
Disclosed but undescribed candidates
SM18: (PCT national phase 2025; IND-enabling) and SM32 (IND-enabling to commence). Both are funded from the July 2025 placing proceeds per the revised use-of-proceeds table (Interim 2026). Targets not publicly disclosed.
-
At least two further unnamed candidates (patents not yet filed), each allocated ~HK$25 m.
-
An "SM17-derived bsAb" appears on the 2026 pipeline chart; details not disclosed.
Services
- None offered commercially. The SYSU-IAS joint laboratory is for internal R&D.
Financial Narrative
Income statement (five-year summary)
Source: Annual Report 2025, Financial Summary (audited). Income tax is nil in all years. Operating income, EBITDA and margins are not meaningful with zero revenue; EBITDA is not disclosed. Revenue CAGR is NM. Net-loss CAGR FY2021–25 is −22.3% (derived); R&D CAGR is −20.0% (derived). The R&D % of net-loss row is derived.
FY2024–FY2025 detail (from AR 2025 MD&A)
FY2024 other income is derived from the disclosed RMB21.7 m increase; FY2024 other expenses are derived from the disclosed RMB21.5 m decrease. FY2024 other expenses included a one-off RMB12.6 m loss on terminating a purchase contract and a RMB9.5 m FX loss.
Commentary. The five-year trajectory is one of deliberate contraction:
FY2021–22 peak spend: Losses of ~RMB285–288 m a year funded SM03 Phase 3, SN1011 multi-indication INDs and SM17 US Phase 1, against IPO cash of HK$1.27 bn.
FY2023–24: R&D fell 25% and 30% respectively as SM03 moved to BLA review and lab spend dropped. FY2024 still carried heavy admin costs (RMB67.7 m), including pre-commercial infrastructure for an RA launch that never happened.
FY2025 inflection: The loss fell 43.3% to RMB105.0 m. Drivers were R&D headcount optimisation (employment costs −RMB9.5 m), admin staff optimisation (−RMB16.4 m), and a RMB21.7 m rise in other income (FX gain +RMB11.4 m, lease-termination gain +RMB7.4 m, grants +RMB4.1 m). Roughly half of the FY2025 improvement is therefore non-operational or one-off.
1H 2026 re-acceleration: Spending rose again as SM17 entered Phase 2 (below).
Interim comparison
Source: Interim Results 2026. Net loss ex-impairment as disclosed by the company.
Commentary. The 1H 2026 underlying loss rose 43% year on year:
-
Phase 2 lab and experiment costs nearly doubled, from RMB13.7 m to RMB28.8 m.
-
Non-cash share-based payments rose (admin +RMB8.2 m; R&D employment +RMB5.2 m), from option and award grants in July 2025, March 2026 and June 2026.
-
Admin depreciation rose RMB7.4 m.
-
Operating cash burn stayed flat at ~RMB30 m, so much of the P&L increase is non-cash.
-
The RMB12.2 m FX gain flatters "other income" again.
Balance sheet
Source: AR 2025 Financial Summary. Totals and working capital are derived. Goodwill is nil. Intangible assets were RMB0.35 m at 31 Dec 2025 and RMB0.17 m at 30 Jun 2026 (Interim 2026).
Net debt is derived as borrowings minus cash; gearing is as reported (borrowings less cash, divided by equity).
30 June 2026 position (Interim 2026):
-
Cash RMB151.8 m; WMPs RMB22.9 m; pledged and restricted deposits RMB21.8 m; total funding RMB196.5 m.
-
Borrowings RMB260.2 m: current RMB114.4 m, non-current RMB145.8 m. Secured RMB146.2 m, unsecured RMB114.1 m. All RMB-denominated at 2.50–3.90%.
-
Maturity: RMB114.4 m within 1 year, RMB107.0 m in year 2, RMB38.8 m in years 3–5.
-
Unutilised facilities RMB311.9 m.
-
Net debt RMB108.4 m (derived); gearing 30.0%.
-
Total equity RMB361.5 m; net current assets RMB62.1 m.
-
Land, buildings and PPE carrying RMB336.3 m are mortgaged; pledged deposit RMB11.9 m.
Cash flow
The January 2024 placing raised HK$73.2 m net. FY2025 FCF is derived.
In 1H 2026, OCF was −RMB29.9 m, capex RMB20.5 m and net bank repayment RMB65.6 m; cash and equivalents fell RMB141.8 m before FX.
Ratios
All derived from the AR 2025 Financial Summary. FY2021 current ratio was 6.06x and liabilities/equity 0.53x. Bank debt/equity was 2.17x at FY2024, 0.64x at FY2025 and 0.72x at 30 June 2026. ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful (negative EBIT and EBITDA, no revenue, no inventory or receivables cycle).
Interpretation. Balance-sheet stress peaked at end-2024: negative working capital, current ratio 0.91x, gearing 185%, and only RMB61.9 m of cash against RMB419 m of debt. The 2025 placings (HK$493.7 m gross across May and August) were therefore a rescue-grade recapitalisation, not opportunistic. They lifted equity 2.6x and cut net debt to near zero.
Cash has since been re-consumed: down RMB155 m in six months, with RMB65.6 m of it spent on debt reduction. The Suzhou sale (RMB280 m) is now the swing factor. Secured borrowings of RMB146.2 m appear to be secured on the Suzhou property, with a maximum mortgage amount of RMB158.4 m. If these are repaid from proceeds, net cash uplift may be roughly RMB120–135 m (analyst estimate, not company guidance). Against an underlying cash burn of roughly RMB60–100 m a year, that implies runway into 2028 absent partnering income, subject to the SM17 Phase 2 cost profile.
Capital raising history (dilution)
Shares outstanding rose from about 1,091.7 m before the May 2025 placing (derived from the 49.17% public-float disclosure) to 1,386.6 m: +27% dilution in 2025 alone.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Segment revenue – R&D of pharmaceutical products (CNY Mn) | 0 | 0 | 0 |
Segment loss before tax (CNY Mn) | -243.1 | -185.1 | -105.0 |
Segment R&D costs (CNY Mn) | 135.4 | 94.8 | 81.6 |
Contribution to group revenue (%) | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGroup Entities
| Entity | Location | Role | Status (Oct 2026) | Source |
|---|---|---|---|---|
SinoMab BioScience Limited (listco) | Hong Kong Science Park | HQ, discovery R&D, management | Active | AR 2025 |
SinoMab BioScience (Shenzhen) Limited (深圳賽樂敏生物科技) | Shenzhen | Holding / operating; parent of Haikou entity | Active | HKEX 12 Mar 2026; etnet |
SinoMab Biopharmaceutical (Haikou) Limited (formerly Hainan SinoMab Biotech) | Haikou, Hainan | Former production base (leased) | Lease terminated 12 Mar 2026 | HKEX 12 Mar 2026 |
MediNexus Pharma (Suzhou) Limited (杏聯藥業(蘇州)) | Suzhou Industrial Park | Owner of Suzhou campus | Vendor in RMB280 m disposal | Interim 2026 |
SinoMab Pty | Australia | Clinical-trial vehicle (SN1011 Phase 1; planned SM17/hC2 trials) | Not publicly detailed | etnet |
Key Financials and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 0 | 0 | 0 | 0 | 0 |
Gross profit (CNY Mn) | 0 | 0 | 0 | 0 | 0 |
R&D costs (CNY Mn) | 199.1 | 180.4 | 135.4 | 94.8 | 81.6 |
Loss before tax (CNY Mn) | -288.2 | -284.2 | -243.1 | -185.1 | -105.0 |
Net loss (CNY Mn) | -288.2 | -284.2 | -243.1 | -185.1 | -105.0 |
EPS basic and diluted (MYR Bn) | -0.29 | -0.29 | -0.24 | -0.17 | -0.09 |
Dividends per share (MYR Bn) | 0 | 0 | 0 | 0 | 0 |
R&D as % of net loss | 69.1 | 63.5 | 55.7 | 51.2 | 77.7 |
Income Statement
| Metric | FY2024 | FY2025 |
|---|---|---|
Other income and gains (CNY Mn) | 7.6 | 29.3 |
R&D – lab consumables and experiment costs (CNY Mn) | 42.3 | 40.9 |
R&D – employment costs (CNY Mn) | 32.5 | 23.0 |
R&D – others (CNY Mn) | 19.9 | 17.8 |
Administrative expenses (CNY Mn) | 67.7 | 46.4 |
Other expenses (CNY Mn) | 22.2 | 0.7 |
Cash Flow and Per-Share Data
| Metric | 1H2025 | 1H2026 |
|---|---|---|
Other income and gains (CNY Mn) | 9.8 | 23.5 |
R&D costs (CNY Mn) | 32.7 | 50.3 |
Administrative expenses (CNY Mn) | 23.7 | 39.0 |
Finance costs (CNY Mn) | 3.0 | 3.3 |
Impairment of non-current assets (CNY Mn) | 0 | 56.3 |
Other expenses (CNY Mn) | 0.2 | 1.8 |
Net loss (CNY Mn) | -49.8 | -127.4 |
Net loss ex-impairment (CNY Mn) | -49.8 | -71.1 |
EPS basic and diluted (MYR Bn) | -0.05 | -0.09 |
Net cash used in operating activities (CNY Mn) | -26.9 | -29.9 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Non-current assets (CNY Mn) | 446.0 | 561.3 | 577.6 | 567.8 | 518.2 |
Current assets (CNY Mn) | 595.7 | 447.1 | 270.2 | 185.3 | 389.9 |
Total assets (CNY Mn) | 1,041.7 | 1,008.3 | 847.8 | 753.1 | 908.1 |
Current liabilities (CNY Mn) | 98.4 | 187.4 | 172.6 | 203.5 | 204.0 |
Non-current liabilities (CNY Mn) | 263.1 | 311.4 | 379.6 | 356.7 | 196.2 |
Total liabilities (CNY Mn) | 361.4 | 498.8 | 552.2 | 560.2 | 400.2 |
Total equity (CNY Mn) | 680.2 | 509.6 | 295.6 | 192.9 | 507.9 |
Working capital (CNY Mn) | 497.3 | 259.7 | 97.5 | -18.2 | 185.9 |
Key Financials
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Cash and cash equivalents (CNY Mn) | 203.7 | 61.9 | 322.7 |
Total funding available incl. WMPs and pledged deposits (CNY Mn) | 0 | 141.4 | 351.5 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Interest-bearing bank borrowings – total (CNY Mn) | 419.3 | 326.8 |
Short-term borrowings (CNY Mn) | 0 | 134.7 |
Long-term borrowings (CNY Mn) | 0 | 192.1 |
Net debt (CNY Mn) | 357.4 | 4.1 |
Gearing ratio, company definition (%) | 185.3 | 0.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2024 | FY2025 |
|---|---|---|
Net cash used in operating activities (CNY Mn) | -130.8 | -70.5 |
Net cash from/(used in) investing activities (CNY Mn) | -94.5 | 16.3 |
Net cash from financing activities (CNY Mn) | 73.3 | 329.4 |
Capital expenditure (CNY Mn) | 0 | 25.3 |
Free cash flow, OCF minus capex (CNY Mn) | 0 | -95.8 |
Net proceeds from share issues (CNY Mn) | 0 | 428.1 |
Dividends paid (CNY Mn) | 0 | 0 |
Share buybacks (CNY Mn) | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE on average equity (%) | -47.8 | -60.4 | -75.8 | -30.0 |
ROA on average total assets (%) | -27.7 | -26.2 | -23.1 | -12.6 |
Current ratio (x) | 2.39 | 1.56 | 0.91 | 1.91 |
Total liabilities / equity (x) | 0.98 | 1.87 | 2.90 | 0.79 |
Share Price & Returns
| Date | Shares issued | Price (HKD) | Net proceeds (HKD Mn) | Source |
|---|---|---|---|---|
Nov 2019 (IPO) | ~182.1 m + over-allotment | 7.60 | 1,272.8 | HKEX 14 Aug 2020 |
Jan 2024 | 56,834,719 | 1.29 | 73.2 | Interim 2026 |
May 2025 | 112,810,817 | 1.10 | 124.0 | Interim 2026 |
Aug 2025 | 182,072,400 | 2.03 | 369.5 | AR 2025 |
Geographic Revenue
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Revenue – Hong Kong (CNY Mn) | 0 | 0 | 0 |
Revenue – Mainland China (CNY Mn) | 0 | 0 | 0 |
Revenue – Rest of world (CNY Mn) | 0 | 0 | 0 |
Share Price History
| Date | Price (HKD) | Context | Source |
|---|---|---|---|
12 Nov 2019 | 7.60 | IPO price | etnet |
26 May 2020 | 3.50 | Private block sale price (Forbest → Grogene) | HKEX |
Jan 2024 | 1.29 | Placing price | Interim 2026 |
May 2025 | 1.10 | Placing price | AR 2025 |
16 Jul 2025 | 2.42 | Intraday after RA BLA withdrawal | Tiger Brokers |
Jul–Aug 2025 | 2.03 | Placing price | AR 2025 |
~3 Sep 2025 | 2.70 | Intraday after 1H 2025 results | Tiger Brokers |
24 Dec 2025 | 1.48 | Last quote on etnet snapshot | etnet |
25 Feb 2026 | 2.10 | Intraday after IBD IND | Tiger Brokers |
~11 Jun 2026 | 1.36 | After a ~26% late-session spike | Tiger Brokers |
9 Jul 2026 | 1.13 | Close, after Suzhou disposal | Investing.com |
24 Jul 2026 | 1.20 | Close (latest verified) | Investing.com |
Valuation Snapshot
| Multiple | Value | Comment |
|---|---|---|
Market cap | ≈HK$1.66 bn (≈RMB1.51 bn) | 1,386.6 m shares |
P/B | ≈4.2x | Equity RMB361.5 m (30 Jun 2026). GuruFocus showed P/TBV 5.06x at HK$1.57 |
EV | ≈RMB1.58 bn | Market cap + debt RMB260.2 m − funding RMB196.5 m |
EV after Suzhou proceeds (pro forma, analyst estimate) | ≈RMB1.30 bn | If RMB280 m received |
Balance Sheet (FY2025–1H2026)
| Metric | FY2025 | 1H2026 |
|---|---|---|
Due within 1 year (CNY Mn) | 134.7 | 114.4 |
Due in year 2 (CNY Mn) | 92.6 | 107.0 |
Due in years 3–5 (CNY Mn) | 99.5 | 38.8 |
Total borrowings (CNY Mn) | 326.8 | 260.2 |
Analyst Conclusions
Management guidance (timelines only; no financial guidance):
-
SM17 Phase 2 AD enrolment complete in 3Q 2026; topline 1Q 2027.
-
Australian SM17 Phase 2 in preparation.
-
IBD: Phase 2a in UC under evaluation.
-
hC2: AA IND to FDA and NMPA in 4Q 2026; first-in-human end-2026 or early 2027.
-
RANKL×SOST bsAb IND in 1H 2027.
-
Suciraslimab SLE Phase 2 under evaluation; Alzheimer's IND enablement.
-
Use-of-proceeds schedule runs through end-2027 and 2028.
Consensus growth expectations: none available (no sell-side coverage identified).
Bull case
-
SM17 replicates Phase 1b in Phase 2. A ~210-patient randomised dataset showing itch and skin efficacy differentiated from IL-4Rα agents, with clean safety, would make SM17 one of few clinically validated IL-25 pathway assets. That would be licensable into a market management sizes at US$27.7 bn globally by 2030.
-
The asset-light pivot plus the Suzhou sale funds the company to the readout. RMB196.5 m of funding plus RMB280 m of gross disposal proceeds, against ~RMB30 m of half-year operating cash burn, removes near-term financing risk through 1Q 2027.
-
Multiple shots on goal in 2026–27. hC2 IND, bsAb IND, IBD Phase 2a and SN1011 milestones via Travere give three to four additional catalysts in a strong China out-licensing environment (157 deals worth US$135.7 bn in 2025).
Bear case
-
Phase 1b over-promise risk. Only 32 patients, single-country, cross-trial comparisons. The alarmin class has historically produced mixed results in AD, and IL-25 is the least-validated alarmin.
-
Track record of strategic reversals and value destruction. The flagship RA BLA was withdrawn after eight years. The SLE pivot has been softened. Manufacturing assets were built and then sold at an impairment. Cumulative losses since FY2021 total RMB1.1 bn against a ~RMB1.5 bn market cap.
-
Structural dilution and governance. Shares rose 27% in 2025; the 20% mandate is renewed; option grants are ongoing. The combined Chair/CEO/CSO role and a pledged 11.46% major holding create overhang. Absent a licence, a further placing before or after the readout is likely.
Key catalysts and monitorables (next 12 months)
-
EGM result and completion of the Suzhou disposal; repayment of secured debt; net cash received.
-
Announcement of completion of SM17 Phase 2 enrolment (~210 patients).
-
SM17 Phase 2 AD topline (guided 1Q 2027).
-
hC2 IND submissions (FDA and NMPA) in 4Q 2026.
-
Any SM17 out-licensing term sheet (upfront size, territory split).
-
SN1011 cash receipts from the Everest/Travere arrangement; Travere development milestones.
-
FY2026 annual results (~March 2027): cash runway, impairment completeness, any going-concern language.
-
New equity issuance under the 20% mandate.
-
IBD Phase 2a initiation decision; Australian SM17 Phase 2 initiation.
-
Board stability, Hainan Haiyao pledge status, and changes in substantial holdings.
Concluding analyst verdict
SinoMab enters late 2026 as a fundamentally different company from the one that listed in 2019. The integrated "discover-develop-manufacture-commercialise" model built around Suciraslimab for rheumatoid arthritis has been dismantled. The BLA was withdrawn in July 2025, the Haikou plant was exited in March 2026, and the Suzhou campus was agreed for sale at an RMB56 m loss in July 2026. What remains is a lean, Hong Kong-centred antibody discovery group with one mid-stage asset of genuine interest (SM17), two preclinical options with credible scientific rationale (hC2 and the RANKL×SOST bispecific), and a small residual interest in a BTK inhibitor now partnered at Nasdaq-company scale.
The financial record is poor by any absolute measure: zero revenue, RMB1.1 bn of losses over five years, and serial dilutive placings at prices far below the HK$7.60 IPO. But the trajectory since 2024 shows discipline. The FY2025 loss fell 43%, the balance sheet was repaired, and capital is now concentrated on SM17. The Phase 2 trial is enrolling ahead of plan and is formulated subcutaneously, the commercially relevant route.
The investment case is therefore binary and time-boxed. At roughly HK$1.7 bn of market value and about RMB1.3 bn of pro forma enterprise value after the Suzhou proceeds, the market is ascribing modest but non-trivial option value to SM17. A clean, differentiated Phase 2 readout in 1Q 2027 that converts into an ex-China licence could plausibly re-rate the equity, given prevailing China-to-global deal economics. A miss would leave a cash shell with preclinical assets and further dilution ahead.
We would characterise SinoMab as a high-risk, catalyst-driven speculative holding. The dominant monitorable is SM17 Phase 2 data quality, followed by disposal completion and any partnering announcement. Governance concentration and the company's record of strategic reversals warrant a persistent risk discount until execution is proven.
Appendix — Principal sources
-
SinoMab BioScience Limited, Interim Results Announcement for the six months ended 30 June 2026 (HKEX, 31 Aug 2026): https://www.hkexnews.hk/listedco/listconews/sehk/2026/0831/2026083102817.pdf
-
SinoMab BioScience Limited, Annual Report 2025 (HKEX, 27 Apr 2026): https://www.hkexnews.hk/listedco/listconews/sehk/2026/0427/2026042701477.pdf
-
HKEX announcements: delay in despatch of circular (27 Jul 2026; 10 Aug 2026); completion of subscriptions (29 May 2025; 29 Aug 2025; 12 & 31 Jan 2024; 16 Nov 2022); supplemental announcement on IPO proceeds (14 Aug 2020); FY2024 annual results (31 Mar 2025); Haikou lease termination (12 Mar 2026); SM17 Phase 2 first-patient-dosed (1 Apr 2026)
-
ClinicalTrials.gov NCT07445919 (SM17-201)
-
CICC (12 Nov 2019); Paul Hastings (12 Nov 2019); Herbert Smith Freehills; HKSTP (30 Dec 2019); ACN Newswire releases (2019–2026)
-
etnet (shareholders, listing price, subsidiaries); Investing.com (prices, market cap, employees); GuruFocus (ISIN, valuation snapshot); financialfilings.com (filing index, LEI); PitchBook profile
-
Tiger Brokers / Bulletin Express, FilingReader, TipRanks, minichart.com.sg (secondary news summaries)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Age (AR 2025) | Background / education | Source |
|---|---|---|---|---|---|
Dr. Shui On LEUNG (梁瑞安) | Executive Director, Chairman, CEO (also CSO function); Chair of Nomination Committee; Remuneration Committee member | Board Apr 2001; CEO Jan 2003 | 66 | Founder. Immunomedics (1991–2000, executive director of biology research); MD, HK Institute of Biotechnology (2000–03); HKEX Biotech Advisory Panel; director of HK Genome Institute; adjunct professor HKUST. BSc/MPhil biochemistry and EMBA (CUHK); DPhil molecular biology (Oxford, 1989); Yale postdoc | AR 2025 |
Ms. Fang LIANG (梁芳) | Executive Director (from 3 Jul 2026); COO (from Mar 2026) | 2026 | 45 | Ex-ED and Chief Strategy Officer, Shanghai Argo Biopharmaceutical (2023–25); SVP Loyal Valley Capital; VP GP Healthcare Capital; Novartis NIBR scientist (2008–17). MBA Manchester; BSc Chemistry Lanzhou | AR 2025; Bulletin Express 27 Jul 2026 |
Ms. Xiaosu WANG (王小素) | Non-executive Director | 19 Dec 2024 | 45 | Securities affairs representative and board-office director, Hainan Haiyao (substantial shareholder) | AR 2025 |
Dr. Jianmin ZHANG (張健民) | Non-executive Director | 6 Sep 2023 | 48 | CSO and head of innovative medicine institute, Hainan Haiyao; ex-ApoPharma. PhD Chemistry (Alberta) | AR 2025 |
Ms. Lei XUE | Non-executive Director (no director's fee) | 12 Jun 2026 | — | — | AGM poll results, 12 Jun 2026 |
Mr. George William Hunter CAUTHERLEY | INED; Audit Committee | 23 Dec 2019 | 83 | 55+ years in medical/pharma distribution in HK, China and SE Asia; Hon DBA Edinburgh Napier; OBE | AR 2025 |
Mr. Ping Cho Terence HON (韓炳祖) | INED; Chair of Audit Committee | 31 Oct 2019 | 66 | 35+ years in finance; INED of Xiabuxiabu, 361 Degrees, Daphne; ex-CFO DTXS, China Dongxiang, TOM Group finance director. FCCA, HKICPA | AR 2025 |
Dr. Chi Ming LEE (李志明) | INED; Chair of Remuneration Committee | 15 Jun 2021 | 72 | Ex-AstraZeneca executive director, Translational Science (CNS/Pain); Bayer; Abbott; CUHK. PhD Cambridge | AR 2025 |
Ms. Chi Sau Giselle LEE (李之秀) | INED; Audit and Nomination Committees | 30 Jun 2025 | 54 | Ex-MD and Head of Asia, Barings AM; Man Group; Deutsche AM. MSc LSE | AR 2025 |
Mr. Nan SHEN (申楠) | INED; Audit and Nomination Committees | 30 Jun 2025 | 44 | MD, Sedgwick Yard (VC); ex-Goldman Sachs and UBS IBD. BA/MA Economics Cambridge; MSc Oxford | AR 2025 |
“—” = not publicly disclosed.
Board of Directors — Dr. Shui On Leung
| Name | Title | Since | Background | Source |
|---|---|---|---|---|
Dr. Shui On Leung | Chairman, CEO, CSO function | 2001/2003 | See above | AR 2025 |
Ms. Fang Liang | COO, Executive Director | Mar 2026 | See above | AR 2025 |
Mr. Jianping HUA (華劍平), 44 | CFO; authorised representative | Jan 2019 | Ex-vice CFO Fosun Pharma; ex-CFO and ED of Sisram Medical; PwC Zhong Tian | AR 2025 |
Dr. Ka Wa Benny CHEUNG, 46 | Director (Quality Control); IP matters | Joined 2010 | PhD Immunology (HKU) | AR 2025 |
Mr. Guolin XU, 42 | Director (Clinical and Regulatory Affairs) | Joined 2009 | MPhil CUHK | AR 2025 |
Mr. Yuande ZHANG, 45 | Director (Marketing) | Feb 2023 | Ex-Chia Tai-Tianqing, Qilu | AR 2025 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
29 May 2025 | INED Dylan Carlo Tinker passed away | — |
6–9 Jun 2025 | Shanchun Wang ceased as President (China) and resigned as ED | Precedes RA BLA withdrawal; China commercial build-out wound down |
30 Jun 2025 | Giselle Lee and Nan Shen appointed INEDs | Restores INED count |
8 Oct 2025 | Company secretary Ivy Chow replaced by Florence Lai (PwC) | Outsourced secretarial function |
Mar 2026 | Fang Liang appointed COO | Brings BD, financing and investor credentials for the out-licensing strategy |
31 Mar 2026 | NED Haigang Chen resigned | Pre-IPO investor representative exits |
1 Apr 2026 | NED Xun Dong (Yunnan Baiyao) resigned | Cornerstone-linked director exits |
12 Jun 2026 | Lei Xue appointed NED | — |
3 Jul 2026 | Fang Liang appointed ED | Second executive on board |
Major Shareholders
| Holder | Shares | % of issued | Date of record | Source |
|---|---|---|---|---|
Hainan Haiyao Co., Ltd. (SZSE: 000566) | 158,882,115 | 11.46 | 29 Aug 2025 | etnet; HKEX completion announcements. Shares charged to China CITIC Bank (security interest) |
Dr. Shui On Leung (CEO/Chairman) | 129,729,200 | 9.36 | 29 Aug 2025 | etnet |
Mr. Jing Qiang (former President; via Grogene and others) | 123,123,070 | 8.88 | 16 Oct 2025 | etnet |
Apricot Capital | 117,922,689 | 8.66 | 15 Aug 2025 | etnet |
Ms. Xu Sijia | 89,802,105 | 6.59 | 15 Aug 2025 | etnet |
Other shareholders (residual) | ~767.1 m | ~55.0 | Derived | — |
Competitive Landscape
Competitor Detail
| SinoMab asset / indication | Competitor (company) | Mechanism | Stage / status | Relative positioning |
|---|---|---|---|---|
SM17 – AD | Dupilumab (Sanofi/Regeneron) | IL-4Rα | Marketed global standard of care | Incumbent; SinoMab claims faster itch relief (cross-trial) |
SM17 – AD | Lebrikizumab (Eli Lilly / Almirall) | IL-13 | Marketed | Type-2 competitor |
SM17 – AD | Tralokinumab (LEO Pharma) | IL-13 | Marketed | Type-2 competitor |
SM17 – AD | Nemolizumab (Galderma) | IL-31RA | Marketed (itch-focused) | Direct competitor on pruritus |
SM17 – AD | Upadacitinib (AbbVie); abrocitinib (Pfizer) | JAK1 | Marketed | High efficacy, boxed safety warnings; SinoMab positions on safety |
SM17 – AD | Rocatinlimab (Amgen/Kyowa Kirin); amlitelimab (Sanofi) | OX40 / OX40L | Late-stage | Next-generation disease modifiers |
SM17 – AD (China) | Stapokibart / CM310 (Keymed Biosciences); other Chinese IL-4Rα biosimilars and novel agents (e.g., Akeso, Hengrui) | IL-4Rα | Marketed or late-stage in China | Price pressure in China market |
SM17 – asthma / CRSwNP | Tezepelumab (Amgen/AstraZeneca); itepekimab (Sanofi/Regeneron) | TSLP / IL-33 alarmins | Marketed / late-stage | Direct alarmin-class competitors; IL-25 is the least-advanced alarmin |
SM17 – IBD | Vedolizumab (Takeda); ustekinumab (J&J); risankizumab (AbbVie); mirikizumab (Lilly); anti-TL1A (Merck, Roche, Sanofi) | Integrin / IL-23 / TL1A | Marketed / late-stage | Crowded; SinoMab differentiates on anti-fibrosis (preclinical) |
Suciraslimab – SLE | Belimumab (GSK); anifrolumab (AstraZeneca); telitacicept (RemeGen, China); obinutuzumab (Roche, LN); CD19 CAR-T and T-cell engagers | BLyS / IFNAR / TACI / CD20 / CD19 | Marketed / emerging | Non-depleting CD22 is novel but preclinical in SLE |
hC2 – AA / vitiligo | Baricitinib (Lilly); ritlecitinib (Pfizer); deuruxolitinib (Sun Pharma); ruxolitinib cream (Incyte); IL-15/CD122 biologics in development | JAK / γc-pathway | Marketed / clinical | Biologic "upstream of JAK" angle |
bsAb – osteoporosis | Denosumab (Amgen and biosimilars); romosozumab (Amgen/UCB); teriparatide/abaloparatide | RANKL / sclerostin / PTH | Marketed | First-in-class bispecific concept; preclinical |
Competitor Detail (Annual)
| Metric | SinoMab (FY2025) |
|---|---|
Revenue | RMB0 |
Net margin | NM (loss RMB105.0 m) |
R&D intensity | NM; R&D RMB81.6 m |
AD asset stage | Phase 2 (China) |



